ALISCA-Breast1 Ph 2 Trial of Alisertib initiated in HR+ve, HER2-Negative Metastatic Breast Cancer November 26, 2024
Promising Preliminary Results of Investigator-Initiated Ph 1 Trial of Keytruda and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors Announced November 19, 2024
Planned Unblinded Data Readout for MIRACLE Ph 3 R/R AML Pivotal Trial Accelerated to H2 2025 November 19, 2024
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025 November 13, 2024
First patient dosed in Ph 1/2 study of Silmitasertib in children and young adults with R/R solid tumors November 12, 2024
Positive TNG462 Clinical Data reported and Update provided on PRMT5 Development Program November 12, 2024
Ph 3 Trial of Adjuvant V940 (mRNA-4157) + KEYTRUDA After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of NSCLC Initiated November 5, 2024
Ph 2 Study of Masofaniten + Enzalutamide in metastatic CRPC Patients terminated; efficacy signals observed will not achieve target product profile November 5, 2024
First Patient Dosed in Ph 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers November 5, 2024
AKIR001 cleared to start Ph 1 clinical trial in multiple cancer types, including anaplastic and iodine-refractory thyroid cancer, SCCHN, and NSCLC November 5, 2024
Ph 1b Clinical Trial expanded to Evaluate TTX-080 in Combination with Cetuximab and Chemotherapy in Advanced Colorectal Cancer November 5, 2024
First Patient Enrolled in Ph 3 Trial of Ivonescimab + Ligufalimab for 1L Treatment of HNSCC Compared to Pembrolizumab November 5, 2024
First Patient Enrolled in Ph 3 Trial of Ivonescimab Combination as 1L Therapy for Biliary Tract Tumors, Compared to Durvalumab November 5, 2024
Three Ph 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous NSCLC November 5, 2024
First Patient Dosed in Ph 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma October 29, 2024
First Patient Dosed in Clinical Collaboration Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC October 29, 2024
Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data Initiated October 22, 2024
First Patient Dosed in Ph 1/2 Cell Therapy Trial of TAC101-CLDN18.2 for the Treatment of Claudin 18.2+ Solid Tumors October 22, 2024
